Running Through Walls Venrock, a venture capital firm

Heather Turner, CEO at Carmot Therapeutics, speaks with Venrock partner Nimish Shah to discuss her time as CEO. Turner shares how she guided the company through its acquisition by Roche, advice for other CEOs on the verge of an acquisition, her perspective on the GLP-1 market and what excites her about the future of biotech. 

Mark McKenna, chairman and CEO at Mirador Therapeutics, speaks with Venrock partner Nimish Shah to discuss his most recent role at Prometheus Biosciences and the beginning of his new company, Mirador. McKenna shares a behind-the-scenes look into leading Prometheus during its acquisition by Merck, why he started Mirador Therapeutics, advice for other CEOs, what he values in a team and more.

We have a special episode today because Venrock’s 8th annual Healthcare Prognosis results are in! From drugs (e.g., GLP-1s, pricing negotiations) to fundraising and optimism around the equity market to cybersecurity and AI regulations - this year’s survey covers it all. In this episode, partners Bryan Roberts and Bob Kocher sit down to share their perspectives on the most interesting findings.

Sami Inkinen, founder and CEO of Virta Health, speaks with Venrock partner Bob Kocher to discuss how Virta has evolved since he was on the podcast seven years ago. Inkinen shares how he views the GLP-1 craze, insights on his go-to-market strategy, advice for founders entering the healthcare market, and how Virta uses AI and technology. 

Latané Conant, Chief Revenue Officer at 6sense, speaks with Venrock partner Brian Ascher to discuss how her previous marketing role prepared her for her promotion to Chief Revenue Officer. Conant shares her approach to keeping product market fit, her opinion on Marketing Qualified Leads (MQLs), how AI could impact sales and marketing and more.

Isan Chen, CEO of MBrace Therapeutics, speaks with Venrock partner Racquel Bracken to discuss his career trajectory leading up to his founding of MBrace. Chen shares the impetus behind his decision to become an oncologist, why he switched from academic medicine to the industry side, lessons learned from years in drug development and more.